Focusing on the development and commercialisation of neurological solutions.
Neurotech International Limited (ASX: NTI) is a biotechnology company focused on developing and commercializing products that improve neurological health. The company leverages innovative technologies and research to create solutions aimed at addressing a range of neurological conditions.
Neurotech is a biopharmaceutical company focused on the development & commercialisation of neurological solutions that improve quality of life. NTI’s current focus is their world-first clinical study utilising NTI164 in the treatment for paediatric Autism Spectrum Disorder (ASD).
The Company is also focused on commercialising Mente, the world’s first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.
More than 20 years’ experience in trading, investment banking & providing corporate advice. Specialises in providing corporate advice & capital raising services to emerging companies seeking business development opportunities and funding from the Australian market. Managing Director of 1861 Capital and co-founder of investment banking firm, Cygnet Capital.
Non-Executive Director
Mr Johnston held the position of President and Chief Executive officer of Johnson and Johnson Pacific, a division of the world’s largest healthcare company for 11 years. Mr Johnston’s career also included senior roles within Australia and overseas with Unilever and Guinness-United Distillers and several prominent industry body roles as past President of ACCORD Australasia Limited, Vice Chairman of AFGC, and Board Member of ASMI.
Pharmacist and consumer health commentator. Leading media health commentator heard each week on television and radio stations across Australia. Extensive knowledge relating to pharmaceutical/ nutraceutical product development, dispensing & marketing in addition to product positioning within the relevant regulatory landscapes (eg. TGA, FDA).
Managing Director and CEO
Dr Filippis isthe Chief Operating Officer of Percheron Therapeutics (ASX:PER),a clinical stageAustralian biotechnology companywith an ongoingPhase IIb clinical trialin the rare paediatric disease,Duchenne musculardystrophy.With 25 years’ biotech experience, Anthony is an internationally proven senior business leader with a deep understanding and knowledge of the biotech industry and capital markets. Anthony is atransaction-focused deal maker, having led and completed severalpartnering (in and out-licensing), M&A transactions with pharmaceutical and biotechcompanies. Throughout his career, hehas raised capital and closed many deals, including with blue-chipcompanies Siemens Healthineers, AstraZeneca, Schering Plough (acquired by Merck), andMeditech (acquired by Alchemia).
Prior to commencing at Percheron Therapeutics in November 2022, Anthony was CEO &Managing Director of Neurosciences Victoria Limited (NSV) for five and half years and before thatCEO of neuroscience drug development company Drawbridge Pharmaceuticals for four years.Anthony is a Founder of Senz Oncology and a Non-Executive Director on the Board of Directorsof VivaZome Therapeutics and Connectivity Limited, and is a member of its Finance, Risk andAudit Committee. He is Chairman of the Commercialisation Committee of the Australian StrokeAlliance and a member of its Risk & Work, Health and Safety Committee.
